Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Non Operating Income (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Other Non Operating Income data on record, last reported at -$151000.0 in Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 91.44% year-over-year to -$151000.0; the TTM value through Dec 2025 reached -$133000.0, up 93.87%, while the annual FY2025 figure was -$133000.0, 93.87% up from the prior year.
  • Other Non Operating Income reached -$151000.0 in Q4 2025 per APLS's latest filing, down from $37000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $219000.0 in Q4 2023 and bottomed at -$99.0 million in Q4 2021.
  • Average Other Non Operating Income over 5 years is -$7.0 million, with a median of -$158000.0 recorded in 2025.
  • Peak YoY movement for Other Non Operating Income: crashed 905.94% in 2024, then skyrocketed 508.33% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at -$99.0 million in 2021, then surged by 99.75% to -$246000.0 in 2022, then soared by 189.02% to $219000.0 in 2023, then plummeted by 905.94% to -$1.8 million in 2024, then surged by 91.44% to -$151000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were -$151000.0 in Q4 2025, $37000.0 in Q3 2025, and $146000.0 in Q2 2025.